BLA submission of ANKTIVA planned in 2025 for 2/3L treatment of patients with NSCLC, who are progressing on checkpoint inhibitors
“The potential to improve outcomes for NSCLC patients who have already relapsed on checkpoints is an unmet need. The combination of administering ANKTIVA plus a checkpoint even after checkpoint relapse/refractory represents a large potential for ANKTIVA to rescue checkpoint failure and prolong overall survival without the toxicities of chemotherapy,” said Dr. Patrick Soon-Shiong, Executive Chairman and Global Chief Medical and Scientific Officer of ImmunityBio. “This submission underscores ImmunityBio’s dedication to advancing cancer treatment and providing new hope for patients battling this aggressive disease. This BLA submission together with our randomized ResQ201A-NSCLC (NCT06745908) Phase 3 trial in NSCLC is a potential stepping stone towards advancing novel immunotherapies in this indication for patients who have failed checkpoint inhibitor therapy.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data